Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343252 · ClinicalTrials.gov registry record · Phase 3
Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 712
- Enrollment target
NCT00343252 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 712 participants.
The verdict
NCT00343252, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 712 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.
Interventions
- DRUG placebo
- DRUG teriparatide
- DRUG risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 712 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343252
The ClinicalTrials.gov registry entry for NCT00343252 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 712 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00343252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343252 about?
NCT00343252 is a clinical study titled "Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis". The purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.
What is the current status of trial NCT00343252?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 712 participants. The study started on 2006-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00343252?
The interventions under investigation include: placebo (DRUG), teriparatide (DRUG), risedronate (DRUG).
Who is sponsoring clinical trial NCT00343252?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.